&Partners’s Axsome Therapeutics AXSM Stock Holding History

&Partners’s Portfolio AXSM Stock Details AXSM Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$1.04M	Buy	6,137 +4,535	+283%	+$783K	0.01%	1278
2025 Q4	$293K	Buy	+1,602	New	+$224K	﹤0.01%	1925

Other funds holding AXSM

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

VPM

Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

DTC

Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

&Partners's AXSM Position: Q1 2026 in Review

&Partners increased its Axsome Therapeutics (AXSM) stake by 283% in Q1 2026, buying an estimated $783K and bringing the position to 6,137 shares worth $1.04M. The position accounts for 0.01% of the portfolio, ranked #1278.

&Partners first reported a position in AXSM in Q4 2025 and has held it in 2 quarters since. 409 funds tracked by Wall St. Rank hold AXSM as of Q1 2026.

&Partners held 6,137 shares of Axsome Therapeutics worth $1.04M as of Q1 2026.
&Partners bought 4,535 Axsome Therapeutics shares in Q1 2026, an estimated $783K.
Axsome Therapeutics made up 0.01% of &Partners's portfolio in Q1 2026, its #1278 holding.
&Partners first reported a position in Axsome Therapeutics in Q4 2025 and has held it in 2 quarters since.
409 funds tracked by Wall St. Rank held Axsome Therapeutics as of Q1 2026.

Based on &Partners's 13F filing for Q1 2026, filed 15 May 2026.